We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Groundbreaking Blood Test Detects Earliest Signs of Pancreatic Cancer Before Symptoms Appear

By LabMedica International staff writers
Posted on 24 Dec 2024

Pancreatic cancer often remains undetected until it has progressed beyond the pancreas, typically because it presents no noticeable symptoms in its early stages. More...

Consequently, pancreatic cancer has one of the highest mortality rates, with survival rates largely unchanged despite advancements in the treatment of other cancers. Early detection is vital for this type of cancer, as most cases are diagnosed at an advanced stage, limiting treatment options. While new treatment options for pancreatic cancer have emerged, their success still relies heavily on the ability to detect the disease early. Now, a groundbreaking blood test can identify pancreatic cancer at its earliest stages, even before symptoms develop. This test works by detecting tumor-derived cell-free DNA that cancer cells release into the bloodstream. These DNA fragments carry distinct signatures unique to pancreatic cancer, allowing for their identification even in very low concentrations.

The BT-Reveal early pancreatic cancer test, developed by Breakthrough Genomics (Irvine, CA, USA), is the first blood-based test of its kind, offering at-risk individuals the ability to detect pancreatic cancer early without the high costs and side effects associated with MRIs and other diagnostic methods. Powered by patented DNA methylation technology, the test detects the earliest signs of pancreatic cancer in circulating cell-free DNA, often before symptoms manifest. DNA methylation involves the switching on and off of DNA molecules to regulate cellular functions. The test identifies abnormal DNA methylation patterns in the blood, which serve as early indicators of pancreatic cancer. On a molecular level, the test analyzes 59 specific DNA methylation regions (biomarkers) that have been strongly associated with pancreatic cancer.

BT-Reveal is a non-invasive, life-saving test that successfully detects 83% of pancreatic cancers, including those in the early Stage 1 and 2. This blood test offers a convenient biochemical alternative to traditional diagnostic methods, helping to screen for pancreatic cancer without the side effects or logistical challenges associated with imaging techniques. It provides an effective and less invasive way to identify pancreatic cancer, especially in clinical settings where quick and reliable detection is crucial. The test has received the FDA's Breakthrough Device Designation and is currently available for high-risk patients through Breakthrough Genomics.

Related Links:
Breakthrough Genomics


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Glucose Tolerance Test
NERL Trutol
New
STI Test
REALQUALITY RQ-SevenSTI
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.